These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35484606)

  • 1. India's ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?
    Sulis G; Pradhan R; Kotwani A; Gandra S
    J Pharm Policy Pract; 2022 Apr; 15(1):33. PubMed ID: 35484606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs.
    McGettigan P; Roderick P; Mahajan R; Kadam A; Pollock AM
    PLoS Med; 2015 May; 12(5):e1001826; discussion e1001826. PubMed ID: 25965416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of rationality of available fixed dose combinations of antibiotics in India.
    Anand P; Kaur N; Verma V; Shafiq N; Malhotra S
    Expert Rev Anti Infect Ther; 2022 May; 20(5):797-808. PubMed ID: 34865581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India.
    McGettigan P; Roderick P; Kadam A; Pollock A
    Br J Clin Pharmacol; 2019 Jan; 85(1):59-70. PubMed ID: 29397576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed dose combinations of anti-tubercular, antimalarial and antiretroviral medicines on the Indian market: critical analysis of ubiquity, sales and regulatory status.
    Ligade VS; Thakar TM; Dengale SJ
    Trop Med Int Health; 2019 Feb; 24(2):238-246. PubMed ID: 30422371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose combinations banned in India: is it the right decision? An eye-opening review.
    Miranda MRH; Dubey A; G S R; Charyulu RN
    Expert Opin Drug Saf; 2019 Oct; 18(10):977-985. PubMed ID: 31374180
    [No Abstract]   [Full Text] [Related]  

  • 7. A study of use of fixed dose combinations in Ahmedabad, India.
    Balat JD; Gandhi AM; Patel PP; Dikshit RK
    Indian J Pharmacol; 2014; 46(5):503-9. PubMed ID: 25298579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of knowledge, attitude and practices about prescribing fixed dose combinations among resident doctors.
    Goswami N; Gandhi A; Patel P; Dikshit R
    Perspect Clin Res; 2013 Apr; 4(2):130-5. PubMed ID: 23833738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India.
    Evans V; Roderick P; Pollock AM
    BMJ Glob Health; 2018; 3(2):e000263. PubMed ID: 29527355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries.
    Bortone B; Jackson C; Hsia Y; Bielicki J; Magrini N; Sharland M
    PLoS One; 2021; 16(1):e0241899. PubMed ID: 33471786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research Letter: Antihypertensive Drugs Market in India: An Insight on Size, Trends, and Prescribing Preferences in the Private Health Sector, 2016-2018.
    Sahoo SK; Pathni AK; Krishna A; Moran AE; Cohn J; Bhatia S; Maheshwari N; Sharma B
    Glob Heart; 2021; 16(1):51. PubMed ID: 34381673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic antibiotic sales and WHO recommendations, India.
    Mehta A; Brhlikova P; McGettigan P; Pollock AM; Roderick P; Farooqui HH
    Bull World Health Organ; 2022 Oct; 100(10):610-619. PubMed ID: 36188020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician's knowledge, attitude and practice of fixed drug combinations: Can we recognize the lacunae?
    Singh A; Dhaneria S; Gupta D
    J Family Med Prim Care; 2022 May; 11(5):2019-2025. PubMed ID: 35800476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Size and usage patterns of private TB drug markets in the high burden countries.
    Wells WA; Ge CF; Patel N; Oh T; Gardiner E; Kimerling ME
    PLoS One; 2011 May; 6(5):e18964. PubMed ID: 21573227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009.
    Wirtz VJ; Mol PG; Verdijk J; Vander Stichele RH; Taxis K
    Trop Med Int Health; 2013 Apr; 18(4):416-25. PubMed ID: 23379471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irrational fixed dose combinations & need for intervention: understanding of dental clinicians and residents.
    Sharma K; Sharma A; Singh V; Pilania D; Sharma YK
    J Clin Diagn Res; 2014 Dec; 8(12):ZC49-52. PubMed ID: 25654031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Availability and rationality of fixed dose combinations available in Kaduna, Nigeria.
    Auwal F; Dahiru MN; Abdu-Aguye SN
    Pharm Pract (Granada); 2019; 17(2):1470. PubMed ID: 31275504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical steroid containing combinations: Burden of adverse effects and why the recent regulatory action may not be enough.
    Jhaj R; Asati DP; Chaudhary D; Sadasivam B
    Indian J Pharmacol; 2021; 53(5):371-376. PubMed ID: 34854405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in hazardous drinking pre, during and post 70-day alcohol sales ban during COVID-19 pandemic in Botswana.
    Maphisa Maphisa J; Ndlovu TBH
    Int J Drug Policy; 2023 Apr; 114():103992. PubMed ID: 36878142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose combinations of antimicrobials: A need for special attention.
    Shafiq N; Kumar G; Gautam V; Ray P; Malhotra S
    Indian J Med Microbiol; 2016; 34(2):208-9. PubMed ID: 27080774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.